235 related articles for article (PubMed ID: 19816883)
1. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice.
Pandruvada SN; Yuvaraj S; Liu X; Sundaram K; Shanmugarajan S; Ries WL; Norris JS; London SD; Reddy SV
Int J Cancer; 2010 May; 126(10):2319-29. PubMed ID: 19816883
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment.
Sambandam Y; Sundaram K; Liu A; Kirkwood KL; Ries WL; Reddy SV
Oncogene; 2013 Jan; 32(1):97-105. PubMed ID: 22330139
[TBL] [Abstract][Full Text] [Related]
3. A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells.
Yuvaraj S; Griffin AC; Sundaram K; Kirkwood KL; Norris JS; Reddy SV
Mol Cancer Res; 2009 Aug; 7(8):1399-407. PubMed ID: 19671684
[TBL] [Abstract][Full Text] [Related]
4. Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells.
Sambandam Y; Ethiraj P; Hathaway-Schrader JD; Novince CM; Panneerselvam E; Sundaram K; Reddy SV
J Cell Physiol; 2018 Aug; 233(8):6125-6134. PubMed ID: 29323724
[TBL] [Abstract][Full Text] [Related]
5. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss.
Zhang X; Junior CR; Liu M; Li F; D'Silva NJ; Kirkwood KL
Oral Oncol; 2013 Feb; 49(2):119-28. PubMed ID: 22989723
[TBL] [Abstract][Full Text] [Related]
6. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY
Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842
[TBL] [Abstract][Full Text] [Related]
7. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma.
Quan J; Zhou C; Johnson NW; Francis G; Dahlstrom JE; Gao J
Pathology; 2012 Apr; 44(3):221-7. PubMed ID: 22406484
[TBL] [Abstract][Full Text] [Related]
9. Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption.
Hwang YS; Lee SK; Park KK; Chung WY
Oral Oncol; 2012 Jan; 48(1):40-8. PubMed ID: 21925926
[TBL] [Abstract][Full Text] [Related]
10. Characterization of different osteoclast phenotypes in the progression of bone invasion by oral squamous cell carcinoma.
Quan J; Hou Y; Long W; Ye S; Wang Z
Oncol Rep; 2018 Mar; 39(3):1043-1051. PubMed ID: 29286135
[TBL] [Abstract][Full Text] [Related]
11. RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells.
Sambandam Y; Sakamuri S; Balasubramanian S; Haque A
J Cell Biochem; 2016 Jan; 117(1):118-25. PubMed ID: 26095774
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of NF-κB suppresses bone invasion by oral squamous cell carcinoma in vivo.
Furuta H; Osawa K; Shin M; Ishikawa A; Matsuo K; Khan M; Aoki K; Ohya K; Okamoto M; Tominaga K; Takahashi T; Nakanishi O; Jimi E
Int J Cancer; 2012 Sep; 131(5):E625-35. PubMed ID: 22262470
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
Martin CK; Werbeck JL; Thudi NK; Lanigan LG; Wolfe TD; Toribio RE; Rosol TJ
Cancer Res; 2010 Nov; 70(21):8607-16. PubMed ID: 20959474
[TBL] [Abstract][Full Text] [Related]
14. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma.
Martin CK; Dirksen WP; Shu ST; Werbeck JL; Thudi NK; Yamaguchi M; Wolfe TD; Heller KN; Rosol TJ
Oral Oncol; 2012 Jun; 48(6):491-9. PubMed ID: 22265717
[TBL] [Abstract][Full Text] [Related]
15. A new osteoclastogenesis pathway induced by cancer cells targeting osteoclast precursor cells.
Wada A; Tsuchiya M; Ozaki-Honda Y; Kayamori K; Sakamoto K; Yamaguchi A; Ikeda T
Biochem Biophys Res Commun; 2019 Jan; 509(1):108-113. PubMed ID: 30578079
[TBL] [Abstract][Full Text] [Related]
16. RANKL triggers resistance to TRAIL-induced cell death in oral squamous cell carcinoma.
Ethiraj P; Sambandam Y; Hathaway-Schrader JD; Haque A; Novince CM; Reddy SV
J Cell Physiol; 2020 Feb; 235(2):1663-1673. PubMed ID: 31309556
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL.
Tohyama R; Kayamori K; Sato K; Hamagaki M; Sakamoto K; Yasuda H; Yamaguchi A
J Oral Pathol Med; 2016 May; 45(5):356-64. PubMed ID: 26859422
[TBL] [Abstract][Full Text] [Related]
18. The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).
Jimi E; Shin M; Furuta H; Tada Y; Kusukawa J
Int J Oncol; 2013 Mar; 42(3):803-9. PubMed ID: 23354319
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3β mediated regulation of matrix metalloproteinase-9 and its involvement in oral squamous cell carcinoma progression and invasion.
Pramanik KK; Nagini S; Singh AK; Mishra P; Kashyap T; Nath N; Alam M; Rana A; Mishra R
Cell Oncol (Dordr); 2018 Feb; 41(1):47-60. PubMed ID: 29134466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
